Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Amoéba
  6. News
  7. Summary
    ALMIB   FR0011051598

AMOÉBA

(ALMIB)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Amoeba : 04/10/21 - Availability of the 2021 Interim Financial report

10/04/2021 | 01:28pm EST

PRESS RELEASE

2021 Interim Financial Report

Chassieu, October 4, 2021, 5.45 pm, AMOEBA (FR0011051598-ALMIB) - producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces today that it has published its Interim Financial Report for 2021.

AMOEBA's shareholders are informed that the interim financial report for the 2021 financial year (ending on December 31st, 2021), filed today with the Autorité des Marchés Financiers (AMF), can be found at the company website: https://amoeba-nature.com/en/investor/financial-documents/.

This report includes:

  • Interim Activity Report
  • Condensed Interim Financial Statements
  • Certification of the person responsible for the interim financial report
  • Statutory Auditors' Review Report on the interim financial information

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-nature.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU

Tel: +33 (0)4 26 69 16 00 - Email: contact@amoeba-nature.com

Société Anonyme au capital de 341 109,20 €

Linkedin: @amoeba-nature - Twitter: @AmoebaNature

RCS Lyon 523 877 215

www.amoeba-nature.com

Contacts:

Amoéba

Calyptus

Valérie FILIATRE

Relations investisseurs & Presse

Directeur Général Adjoint

Grégory BOSSON / Mathieu CALLEUX

+33 4 26 69 16 00

+33 1 53 65 37 90 /91

v.filiatre@amoeba-nature.com

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2021 under number D21-0289 (a copy of which is available on www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU

Tel: +33 (0)4 26 69 16 00 - Email: contact@amoeba-nature.com

Société Anonyme au capital de 341 109,20 €

Linkedin: @amoeba-nature - Twitter: @AmoebaNature

RCS Lyon 523 877 215

www.amoeba-nature.com

Disclaimer

Amoéba SA published this content on 04 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2021 17:23:03 UTC.


© Publicnow 2021
All news about AMOÉBA
01/26AMOEBA : 25/01/22 - Amoéba stenghens its Board of directors by co-opting a new director
PU
01/25AMOEBA : strengthens its board of directors by co-opting a new director
PU
01/07AMOÉBA : Deferral of the 4th tranche of OCAs
PU
01/07AMOEBA : 07/01/22 - Deferral of the 4th tranche of OCA's
PU
2021AMOEBA : 14/12/21 - Update of the regulatory application calendar
PU
2021AMOEBA : update of the regulatory application calendar
PU
2021AMOEBA : 15/11/21 - Postponement of the conclusion of the evaluation of the biocide dossie..
PU
2021AMOEBA : publication of a new paper in the scientific journal « Pathogens »
PU
2021AMOEBA : 20/10/21 - Publication of a new paper in the scientific journal "Pathogens"
PU
2021AMOEBA : 07/10/21 - Amoéba announces the issuance of the third tranche of 60 bonds convert..
PU
More news
Financials
Sales 2020 - - -
Net income 2020 -8,16 M -9,10 M -9,10 M
Net Debt 2020 3,64 M 4,06 M 4,06 M
P/E ratio 2020 -6,20x
Yield 2020 -
Capitalization 15,1 M 16,8 M 16,8 M
EV / Sales 2019 67,7x
EV / Sales 2020 -
Nbr of Employees 20
Free-Float 95,7%
Chart AMOÉBA
Duration : Period :
Amoéba Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMOÉBA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Fabrice Plasson Chairman & Chief Executive Officer
Valérie Filiatre Director, Chief Financial & Administrative Officer
Sandrine Demaneche Scientific Director
Bernard Ambolet Independent Director
Ghislaine Pinochet Independent Director
Sector and Competitors